IN2014CN02806A - - Google Patents
Download PDFInfo
- Publication number
- IN2014CN02806A IN2014CN02806A IN2806CHN2014A IN2014CN02806A IN 2014CN02806 A IN2014CN02806 A IN 2014CN02806A IN 2806CHN2014 A IN2806CHN2014 A IN 2806CHN2014A IN 2014CN02806 A IN2014CN02806 A IN 2014CN02806A
- Authority
- IN
- India
- Prior art keywords
- compounds
- medicaments
- variables
- inhibitors
- formula
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 2
- 108010080805 Factor XIa Proteins 0.000 abstract 1
- 102000003827 Plasma Kallikrein Human genes 0.000 abstract 1
- 108090000113 Plasma Kallikrein Proteins 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161547305P | 2011-10-14 | 2011-10-14 | |
| PCT/US2012/059859 WO2013055984A1 (en) | 2011-10-14 | 2012-10-12 | Substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014CN02806A true IN2014CN02806A (en, 2012) | 2015-07-03 |
Family
ID=47080862
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2806CHN2014 IN2014CN02806A (en, 2012) | 2011-10-14 | 2012-10-12 |
Country Status (7)
| Country | Link |
|---|---|
| US (5) | US9108951B2 (en, 2012) |
| EP (2) | EP2899183B1 (en, 2012) |
| JP (1) | JP6033317B2 (en, 2012) |
| CN (1) | CN103987697B (en, 2012) |
| ES (2) | ES2572908T3 (en, 2012) |
| IN (1) | IN2014CN02806A (en, 2012) |
| WO (1) | WO2013055984A1 (en, 2012) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107973809B (zh) | 2010-02-11 | 2023-06-30 | 百时美施贵宝公司 | 作为因子xia抑制剂的大环类 |
| TW201311689A (zh) | 2011-08-05 | 2013-03-16 | 必治妥美雅史谷比公司 | 作為因子ｘｉａ抑制劑之新穎巨環化合物 |
| TW201319068A (zh) | 2011-08-05 | 2013-05-16 | 必治妥美雅史谷比公司 | 作為ｘｉａ因子抑制劑之環狀ｐ１接合劑 |
| CN103987697B (zh) | 2011-10-14 | 2017-04-26 | 百时美施贵宝公司 | 作为因子xia抑制剂的取代的四氢异喹啉化合物 |
| EA023649B1 (ru) | 2011-10-14 | 2016-06-30 | Бристол-Майерс Сквибб Кампани | ЗАМЕЩЕННЫЕ СОЕДИНЕНИЯ ТЕТРАГИДРОИЗОХИНОЛИНА В КАЧЕСТВЕ ИНГИБИТОРОВ ФАКТОРА XIa |
| CN103987696B (zh) | 2011-10-14 | 2016-12-21 | 百时美施贵宝公司 | 作为因子xia抑制剂的取代的四氢异喹啉化合物 |
| UY34959A (es) | 2012-08-03 | 2014-01-31 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | Dihidropiridona p1 como inhibidores del factor xia |
| DK2880026T3 (en) | 2012-08-03 | 2017-06-06 | Bristol Myers Squibb Co | DIHYDROPYRIDON-P1 AS A FACTOR XIA INHIBITORS |
| WO2014059214A1 (en) * | 2012-10-12 | 2014-04-17 | Bristol-Myers Squibb Company | Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
| WO2014059202A1 (en) | 2012-10-12 | 2014-04-17 | Bristol-Myers Squibb Company | Guanidine substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
| HUE038272T2 (hu) | 2012-10-12 | 2018-10-29 | Bristol Myers Squibb Co | XIA faktor inhibitorának krisztallin alakjai |
| US9834520B2 (en) | 2013-03-14 | 2017-12-05 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| JP6479763B2 (ja) | 2013-03-25 | 2019-03-06 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 第ｘｉａ因子阻害剤としての置換アゾール含有のテトラヒドロイソキノリン |
| EP3018126A4 (en) | 2013-07-03 | 2016-12-07 | Takeda Pharmaceuticals Co | HETEROCYCLIC CONNECTION |
| EP3018123B1 (en) | 2013-07-03 | 2023-05-10 | Takeda Pharmaceutical Company Limited | Amide compound |
| WO2015047973A1 (en) * | 2013-09-27 | 2015-04-02 | Merck Sharp & Dohme Corp. | FACTOR XIa INHIBITORS |
| EP3054944B1 (en) * | 2013-10-07 | 2019-12-04 | Merck Sharp & Dohme Corp. | Factor xia inhibitors |
| SG11201606209PA (en) | 2014-01-31 | 2016-08-30 | Bristol Myers Squibb Co | Macrocycles with hetrocyclic p2' groups as factor xia inhibitors |
| NO2760821T3 (en, 2012) | 2014-01-31 | 2018-03-10 | ||
| WO2015123091A1 (en) | 2014-02-11 | 2015-08-20 | Merck Sharp & Dohme Corp. | Factor xia inhibitors |
| US9944643B2 (en) | 2014-02-11 | 2018-04-17 | Merck Sharp & Dohme Corp. | Factor XIa inhibitors |
| EP3134408B1 (en) * | 2014-04-22 | 2020-08-12 | Merck Sharp & Dohme Corp. | FACTOR XIa INHIBITORS |
| ES2848348T3 (es) | 2014-05-16 | 2021-08-06 | Cumberland Pharmaceuticals Inc | Composiciones y métodos de tratamiento con ifetroban de la fibrosis cardíaca |
| SG11201610729XA (en) | 2014-07-01 | 2017-01-27 | Takeda Pharmaceuticals Co | Heterocyclic compounds and their use as retinoid-related orphan receptor (ror) gamma-t inhibitors |
| US9868727B2 (en) | 2014-07-28 | 2018-01-16 | Merck Sharp & Dohme Corp. | Factor XIa inhibitors |
| US10752640B2 (en) * | 2014-08-01 | 2020-08-25 | Nuevolution A/S | Compounds active towards bromodomains |
| CN105461688B (zh) * | 2014-08-26 | 2017-12-29 | 上海医药工业研究院 | 苯并咪唑化合物k的合成方法 |
| ES2714283T3 (es) | 2014-09-04 | 2019-05-28 | Bristol Myers Squibb Co | Macrociclos de diamida que son inhibidores de FXIa |
| KR102767586B1 (ko) * | 2014-10-01 | 2025-02-17 | 메디뮨 리미티드 | 티카그렐로에 대한 항체 및 이의 사용 방법 |
| US9453018B2 (en) | 2014-10-01 | 2016-09-27 | Bristol-Myers Squibb Company | Pyrimidinones as factor XIa inhibitors |
| EP3310777B1 (en) | 2015-06-19 | 2019-10-09 | Bristol-Myers Squibb Company | Diamide macrocycles as factor xia inhibitors |
| EP3316882A4 (en) | 2015-06-30 | 2019-02-20 | Cumberland Pharmaceuticals Inc. | ANTAGONISTS OF THROMBOXANE RECEPTOR IN MREA / ASTHMA |
| PT3319959T (pt) | 2015-07-06 | 2021-12-06 | Alkermes Inc | Inibidores hetero-halo de histona desacetilase |
| EP3319968A1 (en) | 2015-07-06 | 2018-05-16 | Rodin Therapeutics, Inc. | Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase |
| US10676477B2 (en) | 2015-07-29 | 2020-06-09 | Bristol-Myers Squibb Company | Factor XIa macrocycle inhibitors bearing a non-aromatic P2' group |
| CN107849026B (zh) | 2015-07-29 | 2021-01-01 | 百时美施贵宝公司 | 携带烷基或环烷基p2′部分的因子xia大环抑制剂 |
| EP3368036B1 (en) | 2015-10-29 | 2022-07-20 | Merck Sharp & Dohme LLC | Macrocyclic pyridine-n-oxide derivatives as factor xia inhibitors |
| WO2017074833A1 (en) | 2015-10-29 | 2017-05-04 | Merck Sharp & Dohme Corp. | Macrocyclic spirocarbamate derivatives as factor xia inhibitors, pharmaceutically acceptable compositions and their use |
| AU2016356694B2 (en) | 2015-11-20 | 2021-07-29 | Forma Therapeutics, Inc. | Purinones as ubiquitin-specific protease 1 inhibitors |
| EP3401686B1 (en) * | 2016-01-07 | 2022-10-05 | Fujimori Kogyo Co., Ltd. | Method for analyzing blood characteristics |
| CN107540659A (zh) * | 2016-06-29 | 2018-01-05 | 四川科伦博泰生物医药股份有限公司 | 四氢异喹啉类化合物、其制备方法、药物组合物及其用途 |
| EP3500556B1 (en) | 2016-08-22 | 2023-08-02 | Merck Sharp & Dohme LLC | Pyridine-1-oxide derivatives and their use as factor xia inhibitors |
| AU2018207402B2 (en) | 2017-01-11 | 2023-09-28 | Alkermes, Inc. | Bicyclic inhibitors of histone deacetylase |
| MD3664802T2 (ro) | 2017-08-07 | 2022-07-31 | Alkermes Inc | Inhibitori biciclici ai deacetilazei histonei |
| CN109721539B (zh) * | 2017-10-27 | 2021-07-09 | 天津药物研究院有限公司 | 吡唑酰胺类衍生物及其制备方法和用途 |
| CN109867660A (zh) * | 2017-12-01 | 2019-06-11 | 四川科伦博泰生物医药股份有限公司 | 含季铵离子的四氢异喹啉酰胺化合物及其药物用途 |
| CN111655686B (zh) | 2018-03-28 | 2024-02-09 | 四川科伦博泰生物医药股份有限公司 | 四氢异喹啉类衍生物及其制备方法和用途 |
| JP7413368B2 (ja) * | 2018-09-28 | 2024-01-15 | ヤンセン ファーマシューティカ エヌ．ベー． | モノアシルグリセロールリパーゼ調節因子 |
| WO2020065613A1 (en) * | 2018-09-28 | 2020-04-02 | Janssen Pharmaceutica Nv | Monoacylglycerol lipase modulators |
| US12098148B2 (en) * | 2018-10-22 | 2024-09-24 | C4X Discovery Limited | Therapeutic compounds |
| WO2020094156A1 (zh) * | 2018-11-11 | 2020-05-14 | 上海海雁医药科技有限公司 | 双杂环取代的吡啶-2(1h)-酮衍生物、其制法与医药上的用途 |
| CA3156100A1 (en) | 2019-09-30 | 2021-04-08 | Janssen Pharmaceutica Nv | Radiolabelled mgl pet ligands |
| US20230062486A1 (en) * | 2019-12-19 | 2023-03-02 | Betta Pharmaceuticals Co., Ltd | Kras g12c inhibitor and pharmaceutical use thereof |
| US20230312560A1 (en) * | 2020-07-22 | 2023-10-05 | Janssen Pharmaceutica Nv | Compounds useful as factor xia inhibitors |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1525186A (fr) | 1967-03-29 | 1968-05-17 | Roussel Uclaf | Nouvelles pénicillines et procédé de préparation |
| EP0028489B1 (en) | 1979-11-05 | 1983-10-05 | Beecham Group Plc | Enzyme derivatives, and their preparation |
| US4843062A (en) | 1987-12-23 | 1989-06-27 | American Home Products Corporation | N-acyl-N-napthoylglycines as aldose reductase inhibitors |
| DE4034829A1 (de) | 1990-11-02 | 1992-05-07 | Merck Patent Gmbh | Cyclopeptide |
| JP3190431B2 (ja) | 1991-07-01 | 2001-07-23 | 三菱化学株式会社 | ケトン誘導体 |
| GB9206757D0 (en) | 1992-03-27 | 1992-05-13 | Ferring Bv | Novel peptide receptor ligands |
| WO1996034010A2 (en) | 1995-03-29 | 1996-10-31 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US5624936A (en) | 1995-03-29 | 1997-04-29 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| JP2000507597A (ja) | 1996-04-03 | 2000-06-20 | メルク エンド カンパニー インコーポレーテッド | ファルネシルタンパク質トランスフェラーゼ阻害剤 |
| US5869682A (en) | 1996-04-03 | 1999-02-09 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| PE121699A1 (es) | 1997-02-18 | 1999-12-08 | Boehringer Ingelheim Pharma | Heterociclos biciclicos disustituidos como inhibidores de la trombina |
| ZA985247B (en) | 1997-06-19 | 1999-12-17 | Du Pont Merck Pharma | Guanidine mimics as factor Xa inhibitors. |
| KR100928878B1 (ko) | 1998-03-19 | 2009-11-30 | 버텍스 파마슈티칼스 인코포레이티드 | 카스파제의 억제제 |
| EP1080092B1 (en) | 1998-05-26 | 2008-07-23 | Warner-Lambert Company LLC | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation |
| US6307049B1 (en) | 1998-09-30 | 2001-10-23 | The Procter & Gamble Co. | Heterocyclic 2-substituted ketoamides |
| CZ20012379A3 (cs) | 1999-01-02 | 2001-09-12 | Aventis Pharma Deutschland Gmbh | Nové deriváty malonové kyseliny, způsoby jejich přípravy, použití a farmaceutické přípravky obsahující tyto deriváty (inhibitory aktivity faktoru Xa) |
| EP1016663A1 (en) | 1999-01-02 | 2000-07-05 | Aventis Pharma Deutschland GmbH | Novel malonic acid derivatives, processes for their preparation, their use and pharmaceutical compositions containing them (inhibition of factor Xa activity) |
| DE50008510D1 (de) | 1999-04-09 | 2004-12-09 | Abbott Gmbh & Co Kg | Niedermolekulare inhibitoren von komplementproteasen |
| AU5413600A (en) | 1999-06-14 | 2001-01-02 | Eli Lilly And Company | Compounds |
| DE19962924A1 (de) | 1999-12-24 | 2001-07-05 | Bayer Ag | Substituierte Oxazolidinone und ihre Verwendung |
| EP1125925A1 (en) | 2000-02-15 | 2001-08-22 | Applied Research Systems ARS Holding N.V. | Amine derivatives for the treatment of apoptosis |
| MXPA02010452A (es) * | 2000-05-11 | 2003-06-06 | Bristol Myers Squibb Co | Analogos de tetrahidroisoquinolina utiles como secretagogos de la hormona del crecimiento. |
| SV2003000617A (es) | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
| AR035216A1 (es) | 2000-12-01 | 2004-05-05 | Astrazeneca Ab | Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios |
| AU2002324716A1 (en) | 2001-08-17 | 2003-03-03 | Bristol-Myers Squibb Company Patent Department | Bicyclic hydroxamates as inhibitors of matrix metalloproteinases and/or tnf-$g(a) converting enzyme (tace) |
| CA2726702A1 (en) | 2001-09-21 | 2003-04-03 | Bristol-Myers Squibb Company | Lactam-containing compounds and derivatives thereof as factor xa inhibitors |
| US6649606B1 (en) * | 2001-11-09 | 2003-11-18 | Bristol-Myers Squibb Co. | Tetrahydroisoquinoline analogs as modulators of chemokine receptor activity |
| GB0206033D0 (en) | 2002-03-14 | 2002-04-24 | Pfizer Ltd | Compounds useful in therapy |
| US20040180855A1 (en) | 2003-02-19 | 2004-09-16 | Schumacher William A. | Methods of treating thrombosis with reduced risk of increased bleeding times |
| US7138412B2 (en) | 2003-03-11 | 2006-11-21 | Bristol-Myers Squibb Company | Tetrahydroquinoline derivatives useful as serine protease inhibitors |
| US7129264B2 (en) | 2003-04-16 | 2006-10-31 | Bristol-Myers Squibb Company | Biarylmethyl indolines and indoles as antithromboembolic agents |
| WO2005014533A2 (en) * | 2003-08-08 | 2005-02-17 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions, and methods of use |
| US7417063B2 (en) | 2004-04-13 | 2008-08-26 | Bristol-Myers Squibb Company | Bicyclic heterocycles useful as serine protease inhibitors |
| US7453002B2 (en) | 2004-06-15 | 2008-11-18 | Bristol-Myers Squibb Company | Five-membered heterocycles useful as serine protease inhibitors |
| US7429604B2 (en) | 2004-06-15 | 2008-09-30 | Bristol Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
| JP2008505976A (ja) | 2004-07-12 | 2008-02-28 | アイディーユーエヌ・ファーマスーティカルズ・インコーポレーテッド | テトラペプチド類似体 |
| CN101137412B (zh) | 2005-01-13 | 2012-11-07 | 布里斯托尔-迈尔斯·斯奎布公司 | 用作凝血因子XIa抑制剂的取代的二芳基化合物 |
| WO2006089005A2 (en) | 2005-02-17 | 2006-08-24 | Bristol-Myers Squibb Company | Combination of selective factor viia and/or xia and plasma kallikrein inhibitors |
| WO2006134143A1 (en) | 2005-06-17 | 2006-12-21 | Basf Aktiengesellschaft | Process of producing bleach boosters |
| JP4955009B2 (ja) | 2005-11-11 | 2012-06-20 | エフ．ホフマン−ラ ロシュ アーゲー | 凝固因子Ｘａの阻害剤としての炭素環式縮合環アミン |
| AR058379A1 (es) | 2005-12-14 | 2008-01-30 | Bristol Myers Squibb Co | Derivados de arilpropionamida arilacrilamida arilpropinamida o arilmetilurea como inhibidores del factor xia. proceso de obtencion y composiciones farmaceuticas. |
| US8466295B2 (en) | 2005-12-14 | 2013-06-18 | Bristol-Myers Squibb Company | Thiophene derivatives as factor XIa inhibitors |
| WO2007070818A1 (en) | 2005-12-14 | 2007-06-21 | Bristol-Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
| WO2008024398A2 (en) | 2006-08-23 | 2008-02-28 | Valeant Pharmaceuticals International | Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators |
| CN101605779B (zh) | 2006-12-15 | 2013-11-20 | 百时美施贵宝公司 | 作为凝血因子xia抑制剂的芳基丙酰胺、芳基丙烯酰胺、芳基丙炔酰胺或芳基甲基脲类似物 |
| TW200848024A (en) | 2007-06-13 | 2008-12-16 | Bristol Myers Squibb Co | Dipeptide analogs as coagulation factor inhibitors |
| EA018050B1 (ru) | 2007-06-28 | 2013-05-30 | Новартис Аг | Модуляторы калликреина 7, фармацевтическая композиция, содержащая эти соединения, способ лечения нарушений, опосредуемых активностью калликреина 7 |
| CN102026996B (zh) | 2008-03-13 | 2015-01-07 | 百时美施贵宝公司 | 作为凝血因子xia抑制剂的哒嗪衍生物 |
| WO2010151317A1 (en) | 2009-06-22 | 2010-12-29 | Millennium Pharmaceuticals, Inc. | Substituted hydroxamic acids and uses thereof |
| US8513433B2 (en) | 2009-07-02 | 2013-08-20 | Angion Biomedica Corp. | Small molecule inhibitors of PARP activity |
| US8609676B2 (en) | 2009-08-04 | 2013-12-17 | Merck Sharp & Dohme, Corp. | 4, 5, 6-trisubstituted pyrimidine derivatives as factor IXa inhibitors |
| CN107973809B (zh) | 2010-02-11 | 2023-06-30 | 百时美施贵宝公司 | 作为因子xia抑制剂的大环类 |
| EP2729150B1 (en) | 2011-07-08 | 2016-09-14 | Merck Sharp & Dohme Corp. | Factor ixa inhibitors |
| TW201319068A (zh) | 2011-08-05 | 2013-05-16 | 必治妥美雅史谷比公司 | 作為ｘｉａ因子抑制劑之環狀ｐ１接合劑 |
| TW201311689A (zh) | 2011-08-05 | 2013-03-16 | 必治妥美雅史谷比公司 | 作為因子ｘｉａ抑制劑之新穎巨環化合物 |
| EA023649B1 (ru) | 2011-10-14 | 2016-06-30 | Бристол-Майерс Сквибб Кампани | ЗАМЕЩЕННЫЕ СОЕДИНЕНИЯ ТЕТРАГИДРОИЗОХИНОЛИНА В КАЧЕСТВЕ ИНГИБИТОРОВ ФАКТОРА XIa |
| CN103987697B (zh) | 2011-10-14 | 2017-04-26 | 百时美施贵宝公司 | 作为因子xia抑制剂的取代的四氢异喹啉化合物 |
| CN103987696B (zh) | 2011-10-14 | 2016-12-21 | 百时美施贵宝公司 | 作为因子xia抑制剂的取代的四氢异喹啉化合物 |
| JP6137193B2 (ja) | 2011-12-21 | 2017-05-31 | 小野薬品工業株式会社 | 第ＸＩａ因子阻害剤としての新規ピリジノンおよびピリミジノン誘導体 |
| US20140378474A1 (en) | 2012-01-27 | 2014-12-25 | Novartis Ag | 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors |
| WO2013111107A1 (en) | 2012-01-27 | 2013-08-01 | Novartis Ag | Aminopyridine derivatives as plasma kallikrein inhibitors |
| JP2015083542A (ja) | 2012-02-08 | 2015-04-30 | 大日本住友製薬株式会社 | ３位置換プロリン誘導体 |
| CN104684932B (zh) | 2012-05-10 | 2019-03-12 | 拜耳药业股份公司 | 能够结合凝血因子XI和/或其活化形式因子XIa的抗体及其用途 |
| WO2014014050A1 (ja) | 2012-07-19 | 2014-01-23 | 大日本住友製薬株式会社 | １－（シクロアルキルカルボニル）プロリン誘導体 |
| DK2880026T3 (en) | 2012-08-03 | 2017-06-06 | Bristol Myers Squibb Co | DIHYDROPYRIDON-P1 AS A FACTOR XIA INHIBITORS |
| UY34959A (es) | 2012-08-03 | 2014-01-31 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | Dihidropiridona p1 como inhibidores del factor xia |
-
2012
- 2012-10-12 CN CN201280061670.3A patent/CN103987697B/zh active Active
- 2012-10-12 IN IN2806CHN2014 patent/IN2014CN02806A/en unknown
- 2012-10-12 ES ES12778912.1T patent/ES2572908T3/es active Active
- 2012-10-12 EP EP14195397.6A patent/EP2899183B1/en active Active
- 2012-10-12 EP EP12778912.1A patent/EP2766345B1/en active Active
- 2012-10-12 US US14/350,417 patent/US9108951B2/en active Active
- 2012-10-12 WO PCT/US2012/059859 patent/WO2013055984A1/en active Application Filing
- 2012-10-12 JP JP2014535894A patent/JP6033317B2/ja not_active Expired - Fee Related
- 2012-10-12 ES ES14195397T patent/ES2699226T3/es active Active
-
2015
- 2015-07-15 US US14/799,681 patent/US9394276B2/en active Active
-
2016
- 2016-06-15 US US15/183,051 patent/US9725435B2/en active Active
-
2017
- 2017-07-07 US US15/643,891 patent/US10000466B2/en active Active
-
2018
- 2018-05-17 US US15/982,038 patent/US10906886B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US9725435B2 (en) | 2017-08-08 |
| US20180265494A1 (en) | 2018-09-20 |
| ES2699226T3 (es) | 2019-02-08 |
| CN103987697B (zh) | 2017-04-26 |
| JP6033317B2 (ja) | 2016-11-30 |
| US20140275061A1 (en) | 2014-09-18 |
| EP2899183A1 (en) | 2015-07-29 |
| EP2899183B1 (en) | 2018-09-19 |
| US20150315200A1 (en) | 2015-11-05 |
| WO2013055984A1 (en) | 2013-04-18 |
| ES2572908T3 (es) | 2016-06-03 |
| US9394276B2 (en) | 2016-07-19 |
| US10000466B2 (en) | 2018-06-19 |
| US9108951B2 (en) | 2015-08-18 |
| EP2766345B1 (en) | 2016-03-16 |
| US20170305880A1 (en) | 2017-10-26 |
| CN103987697A (zh) | 2014-08-13 |
| EP2766345A1 (en) | 2014-08-20 |
| US10906886B2 (en) | 2021-02-02 |
| JP2014528479A (ja) | 2014-10-27 |
| US20160289209A1 (en) | 2016-10-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014CN02806A (en, 2012) | ||
| IN2014CN02805A (en, 2012) | ||
| TN2014000155A1 (en) | Substituted tetrahydroisoquinoline compounds as factor xia inhibitors | |
| MX361759B (es) | Compuestos macrocíclicos de dihidropiridona como inhibidores del factor xia y el uso de los mismos en el tratamiento de un trastorno tromboembólico. | |
| MX2015000919A (es) | Dihidropiridona p1 como inhibidores del factor xia. | |
| MY199894A (en) | Prmt5 inhibitors and uses thereof | |
| PH12016500072B1 (en) | Piperidinyl-indole derivatives complement factor b inhibitors and uses thereof | |
| PH12014500199A1 (en) | Indazoles | |
| PH12015500064A1 (en) | Imidazotriazinecarbonitriles useful as kinase inhibitors | |
| MX2016000675A (es) | Derivados de amino-metil-biarilo como inhibidores del factor de complemento d y usos de los mismos. | |
| IN2015DN01156A (en, 2012) | ||
| AU2012214029A8 (en) | Rorgammat inhibitors | |
| IN2014MN02658A (en, 2012) | ||
| MY177344A (en) | Compounds and their methods of use | |
| IN2015DN00598A (en, 2012) | ||
| MY162936A (en) | Macrocycles as factor xia inhibitors | |
| UA111382C2 (uk) | Інгібітори протеїнкінази | |
| IN2014CN03803A (en, 2012) | ||
| PH12014502586A1 (en) | Novel ring-substituted n-pyridinyl amides as kinase inhibitors | |
| JO3115B1 (ar) | مركبات بيريدازينون واستخدامها كمثبطات daao | |
| GB201209587D0 (en) | Therapeutic compounds | |
| IN2014DN06869A (en, 2012) | ||
| MX362879B (es) | Usos novedosos. | |
| MX2013008340A (es) | Novedosas 4-amino-n-hidroxi-benzamidas para el tratamiento de cancer. | |
| NZ700356A (en) | Pyrazole compounds as sglt1 inhibitors |